Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease

Pharmacogenetics

Volumn 8, Issue 3, 1998, Pages 227-238

  Rostami Hodjegan, A ^a   Lennard, M S ^a   Woods, H F ^a   Tucker, G T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

CYP2D6; Lung cancer; Meta analysis; Parkinsons disease

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE;

ACETYLATOR PHENOTYPE; ARTICLE; CANCER RISK; DATA ANALYSIS; DISEASE ASSOCIATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL RECORD; META ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031799305     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199806000-00005     Document Type: Article

References (81)

1. Agúndez JAG, Martínez C, Ladero JM, Ladesma MC, Ramos JM, Martin R et al. Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994; 55:10-14.
2. Agúndez JAG, Jimenez-Jimenez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995; 57:291-298.
3. Akhmedova SN, Pushnova EA, Yakimovsky AF, Avtonomov VV, Schwartz EI. Frequency of specific cytochrome P4502D6B (CYP2D6B) mutant allele in clinically differentiated groups of patients with Parkinson's disease. Biochem Mol Med 1995; 54:88-90.
4. Armstrong M, Daly AK, Cholerton S, Bateman DN. Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339:1017-1018.
5. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenolvpes as markers for susceptibility to lung cancer. Nature 1984; 312:169-170.
6. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; 2:1213-1216.
7. Benítez J, Ladero JM, Jimenez-Jimenez FJ, Martinez C, Puerto AM, Valdivielso MJ et al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53:289-292.
8. Benítez J, Ladero JM, Jara C, Carrillo JA, Cobaleda J, Llerena A et al. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer 1991; 27:158-161.
9. Bordet R, Broly F, Destée A, Libersa C. Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson's disease and diffuse Lewy Body disease. Clin Neuropharm 1994; 17:484-488.
10. Bordet R, Broly F, Destée A, Libersa C, Lafitte JJ. Lack of relation between genetic polymorphism of cytochrome P450 2D6 and sporadic idiopathic Parkinson's disease. Clin Neuropharm 1996a, 19:213-221.
11. Bordet R, Broly F, Destée A, Libersa C. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Adv Neurology 1996b, 69:97-100.
12. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk is dependent on CYP2D6 activity. Cancer Res 1996; 56:251-253.
13. Caporaso N, Hayes RB, Dosemci M, Hoover R, Ayesh R, Hetzel M et al. Lung cancer risk, occupational exposure, and debrisoquine metabolic phenotype. Cancer Res 1989a, 49:3675-3679.
14. Caporaso N, Pickle LW, Bale S, Ayesh, Hetzel M, Idle J. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. Gen Epidemiol 1989b, 6:517-524.
15. Caporaso N, Tucker MA, Hoover RN, Hays RB, Pickle LW, Issaq HJ et al. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990; 82:1264-1272.
16. Chen X, Xia Y, Gresham LS, Molgaard CA, Thomas RG, Galasko D et al. ApoE and CYP2D6 polymorphism with and without Parkinsonism-dementia complex in the people of Chamoro. Guam. Neurology 1996; 47:779-784.
17. Chiba K, Imai H, Yoshino H, Kato J, Ishizaki T, Narabayashi H. Sparteine oxidation in patients with early and late-onset of Parkinson's disease. In: Nagatsu T, Narabayashi H, Yoshida M, editors. Parkinson's disease. From clinical aspects to molecular basis. New York: Springer-Verlag; 1991. pp. 105-109.
18. Christensen PM, Gotzsche PC, Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta analysis. Eur J Clin Pharmacol 1997; 51:389-393.
19. Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine is N-demethylated by cytochromes P450 2D6, 1A2 and 5A4 - implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther 1996; 277:685-690.
20. Comella CL, Tanner CM, Goetz CG, Gans S, Rapp D, Fischer J. Debrisoquine metabolism in Parkinson's disease. Neurology 1987; 37:261-262.
21. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine 4(-(methylnitrosamine)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P450 2D6. Carcinogenesis 1991; 12:1197-1201.
22. D'Errico A, Taioli E, Chen X, Vineis P. Genetic metabolic polymorphism and the risk of cancer: a review of the literature. Biomarkers 1996; 1:149-173.
23. Der Simonian R, Liard N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7:177-188.
24. Diedrich N, Hilger C, Goetz CG, Keipes M, Hentges F, Vieregge P et al. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996; 40:463-465.
25. Doll R, Peto R. The cause of cancer. Oxford: Oxford University Press; 1981. p. 1221.
26. Dolzan V, Rudolf Z, Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 1995; 16:2675-2678.
27. Duche J-C, Joanne C, Barre J, De Cremoux H, Dalphin JC, Brouchard P et al. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol 1991; 31:555-556.
28. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315:629-654.
29. Faccini GB, Puchetti V, Zatti N. Dextromethorphan oxidation phenotypes as markers for susceptibility to lung cancer. Clin Chem 1990; 36:387.
30. Fonne-Pfister R, Bargetzi MJA, Meyer UA. MPTP the neurotoxin inducing Parkinson's disease, is a potent inhibitor of human and rat P450 enzymes (P450buf1, P450db1) catalysing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987; 148:1144-1150.
31. Gasser T, Wszolek ZK, Trofatter J, Ozelius L, Uitti RJ, Lee CS et al. Genetic linkage studies in autosomal dominant Parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994; 36:387-396.
32. Gasser T, Müller-Myhosk B, Supala A, Zimmer E, Wieditz G, Wszolek ZK et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61:518-520.
33. Godjonsson O, Sanz E, Alván G, Aquilonius S-M, Reveriego J. Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30:301-302.
34. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347:773-776.
35. Hennekens CH, Buring JE, Hebert PR. Implications of overviews of randomised trials. Stat Med 1987; 6:397-402.
36. Hetzel MR, Law M, Keal EE, Sloan TP, Idle JR, Smith RL. Is there a genetic component in bronchial carcinoma in smokers? Thorax 1980; 35:709.
37. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 1992; 2:259-263.
38. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993; 3:19-27.
39. Horsmans Y, Desager JP, Harvengt C. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility. Biomed Pharmacother 1991; 45:359-362.
40. Kallio J, Martilla RJ, Rinne UK, Sonnien V, Syvälahti E. Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand 1991; 83:194-197.
41. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphism in vivo. J Natl Cancer Inst 1995; 87:902-907.
42. Kivistö KT, Griese E-U, Stüven T, Fritz P, Friedel G, Kroemer HK et al. Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 1997; 7:295-302.
43. Kondo I, Kanazawa I. Association of Xba I allel (Xba I 44 kb) of the human cytochrome P-450dbI (CYP2D6) gene in Japanese patients with idiopathic Parkinson's disease. In: Nagatsu T, Narabayashi H, Yoshida M, editors. Parkinson's disease. From clinical aspects to molecular basis. New York: Springer-Verlag; 1991. pp. 111-117.
44. Kondo I, Kanazawa I. Debrisoquine hydroxylase and Parkinson's disease. Adv Neurol 1993; 60:338-342.
45. Kösel S, Lücking CB, Egensperger R, Mehraein P, Graeber MB. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-Body Parkinsonism. J Neuroscience Res 1996; 44:174-183.
46. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Gen 1993; 48:166-168.
47. Kurth JH, Phoenix AZ, Hubble JP. Lack of association of CYP2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort. Neurology 1995; 45: A429.
48. Law MR, Hetzel MR, Idle JR. Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 1989; 59:686-687.
49. Legrand M, Stücker I, Marez D, Sabbagh N, Lo-Guidice JM, Broly F. Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility. Carcinogenesis 1996; 17:2267-2269.
50. Liu T-U, Chi C-W, Yang J-C, Cheung S-C, Liu H-C. Debrisoquine metabolism in Chinese patients with Alzheimer's and Parkinson's disease. Mol Chem Neuropathol 1992; 17:31-57.
51. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR. Methodological issues in interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk. Pharmacogenetics 1994; 4:107-108.
52. London SJ, Daly AK, Leathart JBS, Navidi WC, Carpenter CC, Idle JR. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 1997; 17:2267-2269.
53. Lucotte G, Turpin J-C, Gérard N, Panserat S, Krishnamoorthy R. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families. Am J Med Gen 1996; 67:361-365.
54. Luft FC. Bad genes, good people, association linkage, and the environment. J Molec Med 1997; 75:309-311.
55. Martinez C, Agúndez JAG, Ladesma MC, Ladero JM, Martin R, Ramos JM et al. High prevalence of the CYP2D6(C) mutant allele among lung cancer patients. Proceedings of the Fifth European ISSX Meeting: 1993; Tours, France. p. 136.
56. Mazzetti P, Le Guren E, Bonnet A-M, Videdalhet M, Brice M, Agid A. Familial Parkinson's disease and polymorphism at the CYP2D6 locus. J Neurol Neurosurg Psychiatry 1994; 57:871-872.
57. Meillard MN, Bentué-Ferrer D, Brunet-Bourgin F, Morel G, Allain H. Etude de l'hydroxylation de la débrisoquine dans la maladie de Parkinson. Presse Méd 1990; 19:947-949.
58. Nicholl DJ, Bennet P, Ramsden DB, Ho SL, Williams AC. The Hhal polymorphism in the CYP2D6 gene is not associated with Parkinson's disease in a Caucasian population. Eur J Neurol 1995; 2:580-582.
59. Planté-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57:911-913.
60. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet 1987; 2:386.
61. Puchetti V, Faccini GB, Micciolo R, Ghimenton F, Bertrand C, Zatti N. Dextromethorphan test for evaluation of congenital predisposition to lung cancer. Chest 1994; 105:449-453.
62. Ray-Chaudhuri K, Smith C, Gough AC, Novak N, Chamoun V, Wolf CR et al. Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amylotrophic lateral sclerosis. J Neurol Neurosurgery Psychiatry. 1995; 58:109.
63. Roots I, Drakoulis N, Ploch M, Heinmeyer G, Loddenkemper R, Minks T et al. Debrisoquine hydroxylation phenotype, acetylation phenotype and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochensch 1988; 66 (suppl XI):87-97.
64. Roots I, Brockmöller J, Drakoulis N, Loddenkemper R. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class mμ. and arylamine N-acetyltransferase in lung cancer patients. Clin Invest 1992; 70:307-319.
65. Roots I, Drakoulis N, Brockmöller J. Still an open question: does active CYP2D6 predispose to lung cancer. Proceedings of the 8th International Conference on Cytochrome P450: 1993: Lisbon. p. 159.
66. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997; 60:284-295.
67. Sandy MS, Armstrong M, Tanner CM, Daly AK, DiMonte DA, Langston JW et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996; 47:225-230.
68. Shaw GL, Falk RT, Deslauiers J, Frame JN, Nesbitt JC, Pass HI et al. Debrisoquine metabolism and lung cancer risk. Cancer Epidem Biomark Prevention 1995; 4:41-48.
69. Smith CAD, Moss JE, Gough AC, Spurr NK, Wolf CR. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Prospect 1992a, 98:107-112.
70. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992b, 339:1375-1377.
71. Spiers CJ, Murray S, Davies DS, Bola-Mabadeje AF, Boobis AR. Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol 1990; 29:101-109.
72. Steiger MJ, Lledo P, Quinn NP, Marsden CD, Turner P, Jenner PG. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992; 86:159-164.
73. Steventon GB, Heafield MTE, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson's disease. Neurology 1989; 39:883-887.
74. Stücker I, Cosme J, Laurent P, Centée S, Beaune P, Bignon J et al. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 1995; 16:2759-2764.
75. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brogger A et al. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994; 4:47-57.
76. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem 1993; 114:263-266.
77. Weiss W. Cigarette smoking and lung cancer trends. A light at the end of the tunnel? Chest 1997; 111:1414-1416.
78. Wolf CR, Smith CAD, Gough AC, Moss JE, Valliss KA, Howard G et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992; 13:1035-1038.
79. Wolf CR, Smith CAD, Bishop T, Forman D, Gough AC, Spurr NK. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 1994; 4:104-106.
80. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19:251-253.
81. Yusuf S, Peto R, Lewis J, Collins R, Steight P. Beta blockage during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-371.